

# Amparo Santamaría-a Ortiz

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1306194/publications.pdf>

Version: 2024-02-01

101  
papers

1,481  
citations

331670

21  
h-index

361022

35  
g-index

104  
all docs

104  
docs citations

104  
times ranked

1955  
citing authors

#	ARTICLE	IF	CITATIONS
1	Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial. <i>Lancet Haematology</i> , 2020, 7, e18-e27.	4.6	173
2	Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study. <i>Thrombosis and Haemostasis</i> , 2018, 118, 1439-1449.	3.4	154
3	Risk of Ischemic Stroke Associated With Functional Thrombin-Activatable Fibrinolysis Inhibitor Plasma Levels. <i>Stroke</i> , 2003, 34, 2387-2391.	2.0	72
4	Association after linkage analysis indicates that homozygosity for the 46Câ†T polymorphism in the F12 gene is a genetic risk factor for venous thrombosis. <i>Thrombosis and Haemostasis</i> , 2004, 91, 899-904.	3.4	68
5	Homozygosity of the <i>T</i> Allele of the 46 Câ†T Polymorphism in the <i>F12</i> Gene Is a Risk Factor for Ischemic Stroke in the Spanish Population. <i>Stroke</i> , 2004, 35, 1795-1799.	2.0	54
6	Rivaroxaban for treatment of pediatric venous thromboembolism. An Einsteinâ€r phase 3 doseâ€exposureâ€response evaluation. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1672-1685.	3.8	52
7	Bodyweight-adjusted rivaroxaban for children with venous thromboembolism (EINSTEIN-Jr): results from three multicentre, single-arm, phase 2 studies. <i>Lancet Haematology</i> , 2019, 6, e500-e509.	4.6	51
8	Safety and efficacy of rivaroxaban in pediatric cerebral venous thrombosis (EINSTEIN-Jr CVT). <i>Blood Advances</i> , 2020, 4, 6250-6258.	5.2	49
9	Deep vein thrombosis and pulmonary embolism after solid organ transplantation: an unresolved problem. <i>Transplantation Reviews</i> , 2015, 29, 85-92.	2.9	45
10	Successful treatment of pure red cell aplasia after major ABO-incompatible T cell-depleted bone marrow transplantation with erythropoietin. <i>Bone Marrow Transplantation</i> , 1997, 20, 1105-1107.	2.4	40
11	Low-molecular-weight heparin as bridging therapy during interruption of oral anticoagulation in patients undergoing colonoscopy or gastroscopy. <i>International Journal of Clinical Practice</i> , 2007, 61, 212-217.	1.7	35
12	Endothelial protein C receptor polymorphisms and risk of myocardial infarction. <i>Haematologica</i> , 2008, 93, 1358-1363.	3.5	34
13	Bronchoscopy guided by high-resolution computed tomography for the diagnosis of pulmonary infections in patients with hematologic malignancies and normal plain chest X-ray. <i>Haematologica</i> , 2000, 85, 961-6.	3.5	32
14	Risk of acute coronary artery disease associated with functional thrombin activatable fibrinolysis inhibitor plasma level. <i>Haematologica</i> , 2004, 89, 880-1.	3.5	31
15	In Vitro Evidences of Heparinâ€™s Effects on Embryo Implantation and Trophoblast Development. <i>Reproductive Sciences</i> , 2012, 19, 454-462.	2.5	29
16	Skin Necrosis at the Injection Site Induced by Low-Molecular-Weight Heparin: Case Report and Review. <i>Dermatology</i> , 1998, 196, 264-265.	2.1	24
17	Low-molecular-weight heparin, bemiparin, in the outpatient treatment and secondary prophylaxis of venous thromboembolism in standard clinical practice: the ESFERA Study. <i>International Journal of Clinical Practice</i> , 2006, 60, 518-525.	1.7	24
18	Patent foramen ovale and prothrombotic markers in young stroke patients. <i>Blood Coagulation and Fibrinolysis</i> , 2007, 18, 537-542.	1.0	23

#	ARTICLE	IF	CITATIONS
19	Women's Values and Preferences for Thromboprophylaxis during Pregnancy: A Comparison of Direct-choice and Decision Analysis using Patient Specific Utilities. <i>Thrombosis Research</i> , 2015, 136, 341-347.	1.7	23
20	Women's values and preferences and health state valuations for thromboprophylaxis during pregnancy: A cross-sectional interview study. <i>Thrombosis Research</i> , 2016, 140, 22-29.	1.7	23
21	Acute rhabdomyolysis and myonecrosis complicating aeromonas bacteremia in neutropenic patients with hematologic malignancies: report of two cases. <i>Haematologica</i> , 1997, 82, 692-4.	3.5	22
22	Facing real-life with direct oral anticoagulants in patients with nonvalvular atrial fibrillation: outcomes from the first observational and prospective study in a Spanish population. <i>Journal of Comparative Effectiveness Research</i> , 2019, 8, 165-178.	1.4	21
23	Risk of thrombosis associated with oral contraceptives of women from 97 families with inherited thrombophilia: high risk of thrombosis in carriers of the G20210A mutation of the prothrombin gene. <i>Haematologica</i> , 2001, 86, 965-71.	3.5	21
24	Routine clinical practice in the periprocedural management of edoxaban therapy is associated with low risk of bleeding and thromboembolic complications: The prospective, observational, and multinational <i>EMITAF/VTE</i> study. <i>Clinical Cardiology</i> , 2020, 43, 769-780.	1.8	20
25	Does medicine still show an unresolved discrimination against women? Experience in two European university hospitals. <i>Journal of Medical Ethics</i> , 2009, 35, 104-106.	1.8	19
26	Bacteremia by Gram-Negative Bacilli in Patients with Hematologic Malignancies. <i>Acta Haematologica</i> , 1999, 102, 7-11.	1.4	18
27	Transfusion-related acute lung injury associated with an NA1-specific antigranulocyte antibody. <i>Haematologica</i> , 1998, 83, 951-2.	3.5	17
28	What is the clinical impact of low plasminogen activator inhibitor-1 (PAI-1) activity? A case report and study of the incidence of low PAI-1 antigen in a healthy population. <i>Journal of Thrombosis and Haemostasis</i> , 2007, 5, 1565-1566.	3.8	14
29	Clinical presentation and therapeutic management of venous thrombosis in young children: a retrospective analysis. <i>Thrombosis Journal</i> , 2018, 16, 29.	2.1	14
30	Homozygosity of the T allele of the 46 C->T polymorphism in the F12 gene is a risk factor for acute coronary artery disease in the Spanish population. <i>Haematologica</i> , 2004, 89, 878-9.	3.5	14
31	Stroke and pulmonary thromboembolism after a long flight. <i>European Journal of Neurology</i> , 2005, 12, 732-734.	3.3	13
32	Association of functional thrombin-activatable fibrinolysis inhibitor (TAFI) with conventional cardiovascular risk factors and its correlation with other hemostatic factors in a Spanish population. <i>American Journal of Hematology</i> , 2004, 76, 348-352.	4.1	12
33	Diagnostic yield of prothrombotic state studies in cryptogenic stroke. <i>Acta Neurologica Scandinavica</i> , 2006, 114, 250-253.	2.1	11
34	Higher risk of ischaemic stroke associated with factor XI levels in dyslipidaemic patients. <i>International Journal of Clinical Practice</i> , 2007, 61, 1819-1823.	1.7	11
35	Carotid thrombosis after in vitro fertilization: a relatively new thrombotic complication in women. <i>British Journal of Haematology</i> , 2008, 141, 897-899.	2.5	11
36	Thrombosis and hemostasis health in pregnancy: Registries from the International Society on Thrombosis and Haemostasis. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2019, 3, 607-614.	2.3	11

#	ARTICLE	IF	CITATIONS
37	IgM anti-protein S antibodies as a risk factor for venous thrombosis. <i>Haematologica</i> , 2008, 93, 1115-1117.	3.5	10
38	Recomendaciones de la Sociedad Española de Reumatología sobre síndrome antifosfolípido primario. Parte I: Diagnóstico, evaluación y tratamiento. <i>Reumatología Clínica</i> , 2020, 16, 71-86.	0.5	10
39	Serum erythropoietin in the diagnosis of polycythemia vera. A follow-up study. <i>Haematologica</i> , 1997, 82, 406-10.	3.5	10
40	The effect of two different doses of aprotinin on hemostasis in cardiopulmonary bypass surgery: similar transfusion requirements and blood loss. <i>Haematologica</i> , 2000, 85, 1277-84.	3.5	10
41	TETIS study: evaluation of new topical hemostatic agent TT-173 in tooth extraction. <i>Clinical Oral Investigations</i> , 2016, 20, 1055-1063.	3.0	9
42	Edoxaban Management in Diagnostic and Therapeutic Procedures (EMIT-CAF/VTE) Trial design. <i>Clinical Cardiology</i> , 2018, 41, 1123-1129.	1.8	9
43	Quantitative Trait Locus on Chromosome 12q14.1 Influences Variation in Plasma Plasminogen Levels in the San Antonio Family Heart Study. <i>Human Biology</i> , 2007, 79, 515-523.	0.2	8
44	Bemiparin Versus Unfractionated Heparin as Bridging Therapy in the Perioperative Management of Patients on Vitamin K Antagonists: The BERTA Study. <i>Clinical Drug Investigation</i> , 2013, 33, 921-928.	2.2	8
45	Ultrasound evaluation of joint damage and disease activity in adult patients with severe haemophilia A using the HEADUS system. <i>Haemophilia</i> , 2021, 27, 479-487.	2.1	8
46	Beyond hemostasis: the challenge of treating plasminogen deficiency. A report of three cases. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 41, 544-547.	2.1	7
47	Prophylaxis with enoxaparin for prevention of venous thromboembolism after lung transplantation: a retrospective study. <i>Transplant International</i> , 2017, 30, 1266-1274.	1.6	7
48	Quality of electronic treatment records and adherence to prophylaxis in haemophilia and von Willebrand disease: Systematic assessments from an electronic diary. <i>Haemophilia</i> , 2020, 26, 999-1008.	2.1	7
49	The factor VIII treatment history of non-severe hemophilia A: COMMENT. Joint damage in adult patients with mild or moderate hemophilia A evaluated with the HEADUS system. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2638-2641.	3.8	7
50	Mobilization kinetics of peripheral blood progenitor cells after IAPVP-16 salvage chemotherapy plus G-CSF in lymphoproliferative disorders. <i>Bone Marrow Transplantation</i> , 2000, 26, 127-132.	2.4	6
51	Double heterozygosity for Factor V Leiden and Factor V Cambridge mutations associated with low levels of activated protein C resistance in a Spanish thrombophilic family. <i>Thrombosis and Haemostasis</i> , 2005, 93, 1193-1195.	3.4	6
52	Reticulocyte recovery is faster in allogeneic and autologous peripheral blood stem cell transplantation than in bone marrow transplantation. <i>European Journal of Haematology</i> , 1997, 58, 362-364.	2.2	6
53	Platelet function during cardiopulmonary bypass not changed by two different doses of aprotinin. <i>Haematologica</i> , 2000, 85, 381-5.	3.5	6
54	Determining the value contribution of emicizumab (Hemlibra <sup>®</sup> ) for the prophylaxis of haemophilia A with inhibitors in Spain by multi-criteria decision analysis. <i>Global &amp; Regional Health Technology Assessment</i> , 2019, 2019, 228424031988053.	0.1	5

#	ARTICLE	IF	CITATIONS
55	Off-pump technique and replacement therapy for coronary artery bypass surgery in a patient with hemophilia B. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 48, 299-302.	2.1	5
56	Inappropriate secretion of antidiuretic hormone as the initial sign of central nervous system progression of nocardiosis in a patient with chronic lymphocytic leukemia. <i>Haematologica</i> , 1999, 84, 1155-6.	3.5	5
57	Recomendaciones de la Sociedad Española de Reumatología sobre síndrome antifosfolípido primario. Parte II: síndrome antifosfolípido obstétrico y situaciones especiales. <i>Reumatología Clínica</i> , 2020, 16, 133-148.	0.5	4
58	Bone marrow involvement in lymphoblastic lymphoma and small non-cleaved cell lymphoma: the role of trephine biopsy. <i>Haematologica</i> , 1997, 82, 594-5.	3.5	4
59	Role of telemedicine in the management of oral anticoagulation in atrial fibrillation: a practical clinical approach. <i>Future Cardiology</i> , 0, .	1.2	4
60	Clopidogrel in Secondary Ischemic Stroke Prevention. <i>Recent Patents on Cardiovascular Drug Discovery</i> , 2008, 3, 119-125.	1.5	3
61	Complexity of the genetic contribution of different thrombotic risk factors in a Spanish thrombophilic family. <i>Thrombosis and Haemostasis</i> , 2005, 93, 997-998.	3.4	2
62	Antithrombin Cambridge II mutation as a risk factor to develop cerebral venous thrombosis. <i>Thrombosis and Haemostasis</i> , 2008, 99, 443-444.	3.4	2
63	Analytical parameters and vital signs in patients subjected to dental extraction. <i>Journal of Clinical and Experimental Dentistry</i> , 2017, 9, 0-0.	1.2	2
64	Recomendaciones del Grupo Catalán de Trombosis (Tromboc@t Working Group) para el tratamiento de los pacientes que reciben anticoagulantes orales directos. <i>Medicina Clínica</i> , 2018, 151, 210.e1-210.e13.	0.6	2
65	Acquired von Willebrand syndrome in a patient with small lymphocytic lymphoma and Sjögren's syndrome. <i>Blood Coagulation and Fibrinolysis</i> , 2019, 30, 239-242.	1.0	2
66	Recommendations of the Spanish Rheumatology Society for primary antiphospholipid syndrome. Part II: Obstetric antiphospholipid syndrome and special situations. <i>Reumatología Clínica (English Edition)</i> , 2020, 16, 133-148.	0.3	2
67	Elderly patients with atrial fibrillation in routine clinical practice: peri-procedural management of edoxaban oral anticoagulation therapy is associated with a low risk of bleeding and thromboembolic complications: a subset analysis of the prospective, observational, multinational EMIT-AF study. <i>BMC Cardiovascular Disorders</i> , 2020, 20, 504.	1.7	2
68	Use of edoxaban in clinical practice: Comparison of data from the Spanish population in the ETNA-AF-Europe registry. <i>Future Cardiology</i> , 2020, 16, 469-480.	1.2	2
69	Efectos anticancerígenos de las heparinas. <i>Medicina Clínica</i> , 2020, 154, 398-399.	0.6	2
70	Double heterozygosity for Factor V Leiden and Factor V Cambridge mutations associated with low levels of activated protein C resistance in a Spanish thrombophilic family. <i>Thrombosis and Haemostasis</i> , 2005, 93, 1193-5.	3.4	2
71	70 Clinical management using low-molecular-weight heparin (LMWH) in pregnant women with thrombophilia, thromboembolic disease (DVT) or thrombophilia-related maternoplacental syndrome: experience in one center. <i>Thrombosis Research</i> , 2007, 119, S116.	1.7	1
72	CO155: Spanish Registry of Thromboembolic Disease (TD) Related with Hormonal Therapy, Pregnancy, Obstetrics Complications or Assisted Reproductive Techniques in Women (ARP): Preliminary Results of the Team Project (Trombosis En El Ámbito De La Mujer). <i>Thrombosis Research</i> , 2014, 133, S26.	1.7	1

#	ARTICLE	IF	CITATIONS
73	Utilización de heparinas de bajo peso molecular para la profilaxis y el tratamiento de la enfermedad tromboembólica en pacientes embarazadas. <i>Progresos En Obstetricia Y Ginecologia</i> , 2015, 58, 257-263.	0.0	1
74	PSY155 - DETERMINING THE VALUE OF EMICIZUMAB (HEMLIBRA®) FOR THE PROPHYLAXIS TREATMENT OF HAEMOPHILIA A PATIENTS WITH INHIBITORS IN SPAIN BY MULTI-CRITERIA DECISION ANALYSIS (MCDA). <i>Value in Health</i> , 2018, 21, S462-S463.	0.3	1
75	Is there a procoagulant state long-term after lung transplantation? A prospective study. <i>Respiratory Medicine</i> , 2021, 188, 106584.	2.9	1
76	Acute Ischemic Events in Patient Receiving Direct Oral Anticoagulants for Atrial Fibrillation: Incidence, Outcome and Clinical Profile. <i>Blood</i> , 2016, 128, 1442-1442.	1.4	1
77	Are Direct Oral Anticoagulants Plasma Concentrations Associated with the Risk of Postoperative Bleeding? Results from the Real Life Cohort. <i>Blood</i> , 2016, 128, 3819-3819.	1.4	1
78	Complexity of the genetic contribution of different thrombotic risk factors in a Spanish thrombophilic family. <i>Thrombosis and Haemostasis</i> , 2005, 93, 997-8.	3.4	1
79	Institutionalizing fertility management/human sexuality training in Colombian nursing schools. <i>Advances in Contraception: the Official Journal of the Society for the Advancement of Contraception</i> , 1995, 11, 325-334.	0.3	0
80	P.30 Monitoring Anti-Xa activity of tinzaparin and bempiparin [low-molecular-weight-heparins (LMWHs)] at therapeutic dosages during pregnancy. <i>Thrombosis Research</i> , 2011, 127, S136.	1.7	0
81	P.32 The TEAM project: Spanish Registry of Thromboembolic Disease (TD) related with hormonal treatments, pregnancy, obstetrics complications or assisted reproductive procedures in women (ARP). <i>Thrombosis Research</i> , 2011, 127, S136-S137.	1.7	0
82	P.33 Study of variability in the management of thromboembolic disease (TD) in women in Spain: national multicenter study. <i>Thrombosis Research</i> , 2011, 127, S137.	1.7	0
83	C0119 Therapeutic approach to venous paraneoplastic thromboembolism Experience from a single center. <i>Thrombosis Research</i> , 2012, 130, S189.	1.7	0
84	C0120 Thromboembolic events in oncological patients: A single center experience. <i>Thrombosis Research</i> , 2012, 130, S189.	1.7	0
85	P-020 Tinzaparin use in pregnancy: a national, retrospective study of the safety and efficacy profile. <i>Thrombosis Research</i> , 2013, 131, S81.	1.7	0
86			

#	ARTICLE	IF	CITATIONS
91	Progressive Primary Multiple Sclerosis (PPMS): Where Disability is Growing and Treatment is Absent. Value in Health, 2018, 21, S205.	0.3	0
92	Coagulation Screening. , 2018, , 45-51.		0
93	Recommendations of the Spanish Rheumatology Society for primary antiphospholipid syndrome. Part I: Diagnosis, evaluation and treatment. Reumatología Clínica (English Edition), 2020, 16, 71-86.	0.3	0
94	Effect of F7 Gene Promoter Polymorphisms on Factor VII Antigenic Levels.. Blood, 2004, 104, 3962-3962.	1.4	0
95	Making Decisions about Thromboprophylaxis in Pregnancy: Women's Values and Preferences. Blood, 2014, 124, 4833-4833.	1.4	0
96	A Spin-Off in Non Valvular Atrial Fibrillation (NVAf) and Cancer : Doacs As a Safe and Effective Alternative to the Convencional Avks. Blood, 2016, 128, 5021-5021.	1.4	0
97	Facing Deep Venous Thrombosis (DVT) in University Tertiary Hospital: Role of Conventional Thrombophilia Testing in Idiopathic DVT Treatment. Blood, 2019, 134, 4958-4958.	1.4	0
98	Approaching Venous Thromboembolism Disease (DVT) from Another Perspective: Better Management in a Multidisciplinary DVT Unit Improves Clinical Outcomes and Post Thrombotic Syndrome. One-Year Experience in Our Hospital. Blood, 2019, 134, 2431-2431.	1.4	0
99	The association between coagulopathies such as thrombophilia or rare bleeding disorders with the development of gestational vascular complications. Blood Coagulation and Fibrinolysis, 2020, 31, S25-S27.	1.0	0
100	Periprocedural Interruption of Edoxaban in Real World Setting: Results from the Emit AF/VTE Study. Blood, 2020, 136, 13-14.	1.4	0
101	Efecto del tratamiento antirretroviral de gran actividad en la carga viral del virus de la hepatitis C en los primeros tres años de seguimiento. Medicina Clínica, 2003, 121, 408-409.	0.6	0